HC Wainwright Reiterates “Buy” Rating for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $123.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 377.67% from the stock’s previous close.

Separately, StockNews.com downgraded XOMA from a “hold” rating to a “sell” rating in a research report on Friday, December 27th.

XOMA Stock Performance

NASDAQ XOMA traded down $0.52 during trading on Tuesday, reaching $25.75. The company’s stock had a trading volume of 10,351 shares, compared to its average volume of 28,983. XOMA has a 12 month low of $18.57 and a 12 month high of $35.00. The firm has a 50 day moving average price of $29.41 and a 200 day moving average price of $27.95. The firm has a market capitalization of $303.41 million, a price-to-earnings ratio of -7.40 and a beta of 0.92. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28.

Insider Buying and Selling at XOMA

In other news, CEO Owen Hughes sold 21,881 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its stake in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares during the last quarter. Rhumbline Advisers boosted its stake in XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 1,334 shares in the last quarter. Barclays PLC grew its position in XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after acquiring an additional 8,447 shares during the last quarter. Ellsworth Advisors LLC acquired a new position in XOMA during the third quarter worth about $516,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after acquiring an additional 1,968 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.